Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

14
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
14
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

12
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
12
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

11
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
11
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

7
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
7
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

16
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
16
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

12
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
12

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

One-Year Follow-Up of Vascular Intervention Trials Disrupted by the COVID-19 Pandemic: A Use-Case landscape.

Cardiovascular revascularization medicine : including molecular interventions·2022
Same author

Durability of blood pressure reduction after ultrasound renal denervation: three-year follow-up of the treatment arm of the randomised RADIANCE-HTN SOLO trial.

EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology·2022
Same author

Subclinical Leaflet Thrombosis and Anticoagulation After Transcatheter Aortic Valve Replacement: A Review.

JAMA cardiology·2022
Same author

Polymer-Based Versus Polymer-Free Stents in High Bleeding Risk Patients: Final 2-Year Results From Onyx ONE.

JACC. Cardiovascular interventions·2022
Same author

Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants: A Review.

JAMA cardiology·2022
Same author

Treatment Gaps in Guideline-Directed Medical Therapy for Patients Undergoing Higher-Risk Percutaneous Coronary Intervention.

Circulation. Cardiovascular interventions·2022

相关实验视频

Updated: Jul 17, 2025

Delayed Intramyocardial Delivery of Stem Cells after Ischemia Reperfusion Injury in a Murine Model
07:50

Delayed Intramyocardial Delivery of Stem Cells after Ischemia Reperfusion Injury in a Murine Model

Published on: September 3, 2020

4.7K

为缺血性心肌病进行重血管化.

Matthew E Li Kam Wa1, Saba Z Assar2, Ajay J Kirtane2,3

  • 1Coronary Research Group, British Heart Foundation Centre of Research Excellence, King's College London London, UK.

Interventional cardiology (London, England)
|September 1, 2023
PubMed
概括

穿皮冠状动脉干预可以为冠状动脉疾病心力衰竭患者提供类似于绕道手术的好处,但没有手术风险. REVIVED-BCIS2试验为这种方法提供了新的见解.

关键词:
心脏衰竭是因为心脏衰竭.恢复了自己的生命.坚固的 坚固的缺血性心肌病症 缺血性心肌病症通过皮肤进行冠状动脉干预.减少的喷射分数减少的喷射分数稳定的冠状动脉疾病.

更多相关视频

Author Spotlight: Enhancing Coronary Artery Revascularization
05:25

Author Spotlight: Enhancing Coronary Artery Revascularization

Published on: September 15, 2023

751
Model of Ischemia and Reperfusion Injury in Rabbits
06:11

Model of Ischemia and Reperfusion Injury in Rabbits

Published on: November 3, 2023

1.2K

相关实验视频

Last Updated: Jul 17, 2025

Delayed Intramyocardial Delivery of Stem Cells after Ischemia Reperfusion Injury in a Murine Model
07:50

Delayed Intramyocardial Delivery of Stem Cells after Ischemia Reperfusion Injury in a Murine Model

Published on: September 3, 2020

4.7K
Author Spotlight: Enhancing Coronary Artery Revascularization
05:25

Author Spotlight: Enhancing Coronary Artery Revascularization

Published on: September 15, 2023

751
Model of Ischemia and Reperfusion Injury in Rabbits
06:11

Model of Ischemia and Reperfusion Injury in Rabbits

Published on: November 3, 2023

1.2K

科学领域:

  • 心脏病学 心脏病学
  • 干预心脏病学 干预心脏病学
  • 心脏衰竭研究研究

背景情况:

  • 冠状动脉疾病 (CAD) 是心力衰竭的首要原因之一,其中包括心力衰竭的减少射出分数 (HFrEF).
  • 冠状动脉旁路移植 (CABG) 改善了生活质量和长期结果,但在严重受损左心室 (LV) 功能的患者中,具有显著的短期风险.
  • 对于缺血性心肌病患者来说,最佳的再血管化策略仍然是一个临床挑战.

研究的目的:

  • 评估皮肤穿冠状动脉干预 (PCI) 的疗效和安全性,与患有缺血性LV功能障碍的患者的最佳医疗疗 (OMT) 相比.
  • 评估PCI是否可以提供与CABG相似的好处,而没有相关的外科手术风险.
  • 为了在稳定的CAD和HFrEF患者中提供关于重血管化的临床决策信息.

主要方法:

  • REVIVED-BCIS2试验 (NCT01920048) 是一个随机对照试验.
  • 它比较了PCI加OMT与单独OMT在患有缺血性心肌病和可活LV心肌病的患者的结果.
  • 关键的终点包括死亡率,心力衰竭住院和生活质量指标.

主要成果:

  • 在本综述中,试验结果被详细检查.
  • 初步发现表明PCI可能在选定的患者中起作用,但进一步的分析正在进行中.
  • 该评论讨论了这项试验对临床实践和未来研究方向的影响.

结论:

  • REVIVED-BCIS2试验提供了关于PCI在缺血性心肌病中的作用的关键数据.
  • 本综述提出了一种潜在的途径,用于患者选择和重血管化决策.
  • 探讨了关于PCI的长期益处和最佳患者个人资料的未回答的问题.